Literature DB >> 16920212

Long-term performance of interstial fluid pressure and hypoxia as prognostic factors in cervix cancer.

Anthony Fyles1, Michael Milosevic, Melania Pintilie, Ami Syed, Wilf Levin, Lee Manchul, Richard P Hill.   

Abstract

OBJECTIVES: Hypoxia and high interstitial fluid pressure (IFP) have been shown to independently predict for nodal and distant metastases, as well as survival, in patients with cervix cancer. Using data from our prospective trial, we updated a cohort of patients treated with definitive radiation alone without chemotherapy, to assess the long-term prognostic impact of these microenvironmental features.
METHODS: Between April 1994 and January 1999, 107 eligible patients with cervix cancer were entered into a prospective study of tumor oxygenation and IFP prior to primary radiation therapy. Oxygenation data are presented as the hypoxic proportion, defined as the percentage of pO(2) readings <5 mm Hg (abbreviated as HP(5)). Patients with HP(5) values >50% were considered to have hypoxic tumors. IFP is presented in mmHg, divided into high and low IFP groups by the median value. Patients ranged in age from 23 to 78 years with a mean of 53 years. The maximum tumor size ranged from 2 to 10 cm, with a median diameter of 5 cm. FIGO stage was IB in 28 patients, IIA in 4, IIB in 42 and IIIB in 33 patients. Twenty-two patients (21%) had evidence of pelvic lymph node involvement on staging CT abdomen/pelvis or MR pelvis. HP(5) ranged from 0% to 99% with a median of 48%. IFP ranged from -3 to 48 mm Hg (median 19 mm Hg). Median follow-up was 6.7 years (range 0.9-10.6).
RESULTS: Disease-free survival (DFS) at 5 years was 50%. Five year DFS was 42% for patients with hypoxic tumors (HP(5)>50%), and 58% in patients with oxygenated tumors (HR 1.01 per %, p=0.05). DFS at 5 years was 42% for patients with interstitial hypertension (IFP >19 mm Hg), and 63% in patients with IFP <or=19 mm Hg (HR 1.05 per mmHg, p=0.001). In a multivariate analysis only tumor size (HR 1.2, p=0.009) pelvic nodal metastases (HR 3.3, p=0.0004) and IFP (HR 1.06, p=0.0005) were predictive of DFS. Because an interaction between nodal status and oxygenation was observed (p=0.03), further analysis indicated a borderline significant impact of HP(5) in addition to tumor size in node negative patients (HR 1.01, p=0.06). These results were similar when local or distant relapse was used as an endpoint.
CONCLUSIONS: These results confirm our initial finding of the strong independent prognostic impact of IFP for relapse and survival in patients with cervix cancer. In contrast, the independent prognostic impact of HP(5) is of borderline significance and is limited to patients without imaging evidence of nodal metastases. However, these findings do not diminish the biologic significance of hypoxia, or the role of hypoxia and IFP as biomarkers of treatment response and as therapeutic targets.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16920212     DOI: 10.1016/j.radonc.2006.07.014

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  32 in total

1.  High interstitial fluid pressure promotes tumor progression through inducing lymphatic metastasis-related protein expressions in oral squamous cell carcinoma.

Authors:  T Yu; Z Wang; K Liu; Y Wu; J Fan; J Chen; C Li; G Zhu; L Li
Journal:  Clin Transl Oncol       Date:  2013-10-02       Impact factor: 3.405

2.  Influence of hypoxia-dependent factors on the progression of neuroblastoma.

Authors:  Helen M Ameis; Astrid Drenckhan; Morton Freytag; Jakob R Izbicki; Claudiu T Supuran; Konrad Reinshagen; Stefan Holland-Cunz; Stephanie J Gros
Journal:  Pediatr Surg Int       Date:  2015-10-28       Impact factor: 1.827

3.  Moving Forward in Cervical Cancer: Enhancing Susceptibility to DNA Repair Inhibition and Damage, an NCI Clinical Trials Planning Meeting Report.

Authors:  Matthew M Harkenrider; Merry Jennifer Markham; Don S Dizon; Anuja Jhingran; Ritu Salani; Ramy K Serour; Jean Lynn; Elise C Kohn
Journal:  J Natl Cancer Inst       Date:  2020-11-01       Impact factor: 13.506

4.  Oxygenation in cervical cancer and normal uterine cervix assessed using blood oxygenation level-dependent (BOLD) MRI at 3T.

Authors:  Rami R Hallac; Yao Ding; Qing Yuan; Roderick W McColl; Jayanthi Lea; Robert D Sims; Paul T Weatherall; Ralph P Mason
Journal:  NMR Biomed       Date:  2012-05-23       Impact factor: 4.044

5.  The Microenvironment of Cervical Carcinoma Xenografts: Associations with Lymph Node Metastasis and Its Assessment by DCE-MRI.

Authors:  Christine Ellingsen; Stefan Walenta; Tord Hompland; Wolfgang Mueller-Klieser; Einar K Rofstad
Journal:  Transl Oncol       Date:  2013-10-01       Impact factor: 4.243

Review 6.  Physical traits of cancer.

Authors:  Hadi T Nia; Lance L Munn; Rakesh K Jain
Journal:  Science       Date:  2020-10-30       Impact factor: 47.728

7.  Human cervical carcinoma xenograft models for studies of the physiological microenvironment of tumors.

Authors:  Christine Ellingsen; Ingrid Natvig; Jon-Vidar Gaustad; Kristine Gulliksrud; Tormod A M Egeland; Einar K Rofstad
Journal:  J Cancer Res Clin Oncol       Date:  2009-02-13       Impact factor: 4.553

8.  Radiocurability is associated with interstitial fluid pressure in human tumor xenografts.

Authors:  Einar K Rofstad; Jon-Vidar Gaustad; Kjetil G Brurberg; Berit Mathiesen; Kanthi Galappathi; Trude G Simonsen
Journal:  Neoplasia       Date:  2009-11       Impact factor: 5.715

9.  Characterizing gradient echo signal decays in gynecologic cancers at 3T using a Gaussian augmentation of the monoexponential (GAME) model.

Authors:  Pelin A Ciris; Mukund Balasubramanian; Antonio L Damato; Ravi T Seethamraju; Clare M Tempany-Afdhal; Robert V Mulkern; Akila N Viswanathan
Journal:  J Magn Reson Imaging       Date:  2016-03-12       Impact factor: 4.813

10.  Proton imaging of siloxanes to map tissue oxygenation levels (PISTOL): a tool for quantitative tissue oximetry.

Authors:  Vikram D Kodibagkar; Xianghui Wang; Jesús Pacheco-Torres; Praveen Gulaka; Ralph P Mason
Journal:  NMR Biomed       Date:  2008-10       Impact factor: 4.044

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.